AMARANTE, I. et al. Full recovery over one year of the overlap syndrome scleromyositis to maintenance therapy with mycophenolate mofetil and rituximab, which relapsed within 8 months of discontinuation. European Journal of Case Reports in Internal Medicine, v. 12, n. 5, 5 May2025.